Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells

Journal of Inflammation (United Kingdom)

Volumn 10, Issue 1, 2013, Pages

  Son, Deok Soo ^a   Kabir, Syeda M ^a   Dong, Yuanlin ^a   Lee, Eunsook ^a   Adunyah, Samuel E ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Chemokines; EGF; NF B; Ovarian cancer; TNF

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR5; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; EPIDERMAL GROWTH FACTOR; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P52; TUMOR NECROSIS FACTOR;

ARTICLE; CANCER CELL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84879631373     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-10-25     Document Type: Article

References (55)

1. Possible role of ovarian epithelial inflammation in ovarian cancer. Ness RB, Cottreau C, Natl Cancer Inst 1999 91 1459 1467 10.1093/jnci/91.17.1459
2. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL, Mol Cell Endocrinol 2006 247 4 21 10.1016/j.mce.2005.09.014 16297528
3. Inflammation and ovarian cancer. Macciò A, Madeddu C, Cytokine 2012 58 133 147 10.1016/j.cyto.2012.01.015 22349527
4. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, Burke F, et al. Mol Cancer Ther 2006 5 382 390 10.1158/1535-7163. MCT-05-0303 16505113
5. Tumor necrosis factor-α and its receptors in epithelial ovarian cancer. Dobrzycka B, Terlikowski SJ, Garbowicz M, Niklińska W, Bernaczyk PS, Nikliński J, et al. Folia Histochem Cytobiol 2009 47 609 613 20430728
6. Circulating levels of TNF-α and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Dobrzycka B, Terlikowski SJ, Kowalczuk O, Kinalski M, Eur Cytokine Netw 2009 20 131 134 19825522
7. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al. Cancer Res 2012 72 66 75 22065722
8. Chemokines: key players in cancer progression and metastasis. Singh R, Lillard JW Jr, Singh S, Front Biosci 2011 3 1569 1582
9. The chemokine system and cancer. Balkwill FR, J Pathol 2012 226 148 157 10.1002/path.3029 21989643
10. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Son DS, Parl AK, Rice VM, Khabele D, Cancer Biol Ther 2007 6 1302 1312 17712227
11. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL, Cancer Res 2005 65 10355 10362 10.1158/0008-5472.CAN- 05-0957 16288025
12. Epidermal growth factor receptor (EGFR) signaling in cancer. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Gene 2006 366 2 16 10.1016/j.gene.2005.10.018 16377102
13. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Lafky JM, Wilken JA, Baron AT, Maihle NJ, Biochim Biophys Acta 2008 1785 232 265 18291115
14. Early events in the pathogenesis of epithelial ovarian cancer. Landen CN Jr, Birrer MJ, Sood AK, J Clin Oncol 2008 26 995 1005 10.1200/JCO.2006.07.9970 18195328
15. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, et al. J Oncol 2010 2010 568938 20037743
16. Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Moscova M, Marsh DJ, Baxter RC, Cancer Res 2006 66 1376 1383 10.1158/0008-5472.CAN-05-2666 16452192
17. The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells. Guo Z, Cai S, Fang R, Chen H, Du J, Tan Y, et al. Colloids Surf B Biointerfaces 2007 60 1 6 10.1016/j.colsurfb.2007.05.013 17601710
18. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, et al. Proc Natl Acad Sci USA 2006 103 16472 16477 10.1073/pnas.0605752103 17060621
19. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, et al. J Biol Chem 2002 277 24584 24593 10.1074/jbc.M112275200 11978786
20. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, et al. Neuro Endocrinol Lett 2010 31 375 383 20588232
21. Augmentation of CCL17 and CCL28 gene expression by TNF-α, IL-1β, or IFN-γ in cultured canine keratinocytes. Shibata S, Maeda S, Maeda S, Chimura N, Kondo N, Fukata T, Res Vet Sci 2010 88 422 426 10.1016/j.rvsc.2009.11.011 20022349
22. IL-1β and TNF-α induce increased expression of CCL28 by airway epithelial cells via an NFκB-dependent pathway. O'Gorman MT, Jatoi NA, Lane SJ, Mahon BP, Cell Immunol 2005 238 87 96 10.1016/j.cellimm.2006.02.003 16581045
23. CXC chemokine ligand 16 in periodontal diseases: expression in diseased tissues and production by cytokine-stimulated human gingival fibroblasts. Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T, Clin Exp Immunol 2007 149 146 154 10.1111/j.1365-2249.2007.03398.x 17459077
24. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. Wågsäter D, Olofsson PS, Norgren L, Stenberg B, Sirsjö A, Biochem Biophys Res Commun 2004 325 1187 1193 10.1016/j.bbrc.2004.10.160 15555552
25. The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells. Day C, Patel R, Guillen C, Wardlaw AJ, Exp Lung Res 2009 35 272 283 10.1080/01902140802635517 19415545
26. The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. Chandrasekar B, Mummidi S, Valente AJ, Patel DN, Bailey SR, Freeman GL, et al. J Biol Chem 2005 280 26263 26277 10.1074/jbc.M502586200 15890643
27. Heparin-binding epidermal growth factor-like growth factor inhibits cytokine-induced NF-κB activation and nitric oxide production via activation of the phosphatidylinositol 3-kinase pathway. Mehta VB, Besner GE, J Immunol 2005 175 1911 1918 16034135
28. Epidermal growth factor activates nuclear factor-κB in human proximal tubule cells. Haussler U, von Wichert G, Schmid RM, Keller F, Schneider G, Am J Physiol Renal Physiol 2005 289 808 F815 10.1152/ajprenal.00434.2003 15798085
29. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM, Int J Cancer 2003 105 735 746 10.1002/ijc.11081 12767057
30. Tumor necrosis factor alpha and epidermal growth factor act additively to inhibit matrix gene expression by chondrocyte. Klooster AR, Bernier SM, Arthritis Res Ther 2005 7 127 R138 10.1186/ar1464 15642133
31. Expression of proangiogenic chemokine Gro 1 in low and high metastatic variants of Pam murine squamous cell carcinoma is differentially regulated by IL-1α, EGF and TGF-β1 through NF-κB dependent and independent mechanisms. Loukinova E, Chen Z, Van Waes C, Dong G, Int J Cancer 2001 94 637 644 10.1002/ijc.1514 11745457
32. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ, Cancer Res 2000 60 5334 5339 11034066
33. Multiple control of interleukin-8 gene expression. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M, J Leukoc Biol 2002 72 847 855 12429706
34. Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells. Haim K, Weitzenfeld P, Meshel T, Ben-Baruch A, Neoplasia 2011 13 230 243 21390186
35. MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cells. Le Quément C, Guénon I, Gillon JY, Lagente V, Boichot E, Am J Physiol Lung Cell Mol Physiol 2008 294 1076 L1084 10.1152/ajplung.00489.2007 18390828
36. Induction of macrophage-inflammatory protein-3α gene expression by TNF-dependent NF-κB activation. Sugita S, Kohno T, Yamamoto K, Imaizumi Y, Nakajima H, Ishimaru T, et al. J Immunol 2002 168 5621 5628 12023359
37. Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein-3α/CCL20 in mucosal epithelial cells through NF-κB. Fujiie S, Hieshima K, Izawa D, Nakayama T, Fujisawa R, Ohyanagi H, et al. Int Immunol 2001 13 1255 1263 10.1093/intimm/13.10.1255 11581170
38. CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: role of NF-κB. Calvayrac O, Rodríguez-Calvo R, Alonso J, Orbe J, Martín-Ventura JL, Guadall A, et al. Arterioscler Thromb Vasc Biol 2011 31 2733 2741 10.1161/ATVBAHA.111. 235721 21852561
39. Human papillomavirus type 8 interferes with a novel C/EBPβ-mediated mechanism of keratinocyte CCL20 chemokine expression and Langerhans cell migration. Sperling T, Ołdak M, Walch-Rückheim B, Wickenhauser C, Doorbar J, Pfister H, et al. PLoS Pathog 2012 8 1002833 10.1371/journal.ppat. 1002833 22911498
40. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Meares GP, Ma X, Qin H, Benveniste EN, Glia 2012 60 771 781 10.1002/glia.22307 22319003
41. miR-21 functionally interacts with the 3′UTR of chemokine CCL20 and down-regulates CCL20 expression in miR-21 transfected colorectal cancer cells. Vicinus B, Rubie C, Faust SK, Frick VO, Ghadjar P, Wagner M, et al. Cancer Lett 2012 316 105 112 10.1016/j.canlet.2011.10.031 22099878
42. IL-17F induces CCL20 in bronchial epithelial cells. Nozato K, Fujita J, Kawaguchi M, Ohara G, Morishima Y, Ishii Y, et al. J Allergy 2011 2011 587204
43. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT, J Invest Dermatol 2011 131 329 337 10.1038/jid.2010.313 20962853
44. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma. Guo L, Cui ZM, Zhang J, Huang Y, Chin J Cancer 2011 30 336 343 10.5732/cjc.010.10490 21527066
45. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, et al. Cancer Res 2011 71 5522 5534 10.1158/0008-5472.CAN-10-3143 21742774
46. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Meijer J, Zeelenberg IS, Sipos B, Roos E, Cancer Res 2006 66 9576 9582 10.1158/0008-5472.CAN-06-1507 17018614
47. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, et al. J Clin Invest 2012 122 3127 3144 10.1172/JCI61067 22922255
48. Targeting IL-8 in colorectal cancer. Ning Y, Lenz HJ, Expert Opin Ther Targets 2012 in press
49. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of bladder cancer. Reis ST, Leite KR, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, et al. BMC Urol 2012 12 18 10.1186/1471-2490-12-18 22695075
50. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Shi Z, Yang WM, Chen LP, Yang DH, Zhou Q, Zhu J, et al. Breast Cancer Res Treat 2012 135 737 747 10.1007/s10549-012-2196-0 22923236
51. Overexpression of CCL20 and its receptor CCR6 predicts poor clinical prognosis in human gliomas. Wang L, Qin H, Li L, Zhang Y, Tu Y, Feng F, et al. Med Oncol 2012 29 3491 3497 10.1007/s12032-012-0314-9 22926920
52. High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. Ding X, Wang K, Wang H, Zhang G, Liu Y, Yang Q, et al. J Gastrointest Surg 2012 16 828 836 10.1007/s11605-011-1775-4 22072303
53. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. Kirshberg S, Izhar U, Amir G, Demma J, Vernea F, Beider K, et al. PLoS One 2011 6 24856 10.1371/journal.pone.0024856 21949768
54. CCL20/CCR6 expression profile in pancreatic cancer. Rubie C, Frick VO, Ghadjar P, Wagner M, Grimm H, Vicinus B, et al. J Transl Med 2010 8 45 10.1186/1479-5876-8-45 20459729
55. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. Beider K, Abraham M, Begin M, Wald H, Weiss ID, Wald O, et al. PLoS One 2009 4 5125 10.1371/journal.pone.0005125 19340288